Investors love to back a winner — except for short-sellers. These contrarian traders prefer betting stocks will fall, and the further the better.Many investors don’t like short-sellers because they are looking for a stock to fail. Yet, it’s a normal part of the market. Stocks rise and fall, and profiting from a stock’s decline isn’t bad. The short-sellers aren’t causing the stock to fall, the business is.How short-selling works is an investor borrows a company’s shares and sells them. Sometime later, he buy ...

Nvidia’s (NASDAQ:NVDA) leadership in artificial intelligence has attracted significant investor and trader interest. This has contributed to its 750% gains since the beginning of 2023, when Nvidia witnessed a golden cross between its 50-day and 200-day moving averages (MAs). On June 20, NVDA stock topped out. Now, based on recent Nvidia technical analysis, the pullback appears poised to continue while the stock trades below the 50-day MA around $120 per share.Nvidia’s impressive revenue and earnings growth ...

Core Viewpoint - The merger agreement between NLS Pharmaceutics and Kadimastem will result in Kadimastem investors acquiring 85% of the combined company's stock, with the new entity operating under the Kadimastem name [1] Group 1: Merger Details - NLS Pharmaceutics will be acquired by a wholly-owned subsidiary of Kadimastem, leading to a significant ownership shift [1] - The merger is expected to be executed in September, with a closing date anticipated by the end of the year [3] - Following the merger, nearly all members of the NLS Pharmaceutics board and executive team will depart, except for one [6] Group 2: Stock Market Impact - NLS Pharmaceutics stock has seen a substantial increase of 47.8% as of Monday morning following the merger announcement [7] - Heavy trading activity has been noted, with over 98 million shares being traded, significantly higher than the average daily volume of about 10 million shares [4][5] Group 3: Future Developments - The combined company will continue to develop NLS Pharmaceutics' Dual Orexin Agonist platform and Kadimastem's allogeneic cell products [6] - NLS shareholders will have the opportunity to benefit from the equity of the merged company and the value of legacy assets through a contingent value rights agreement [7]

Abbott Labs (NYSE:ABT) stock is falling more than 4% after a St. Louis jury found its premature infant baby formula responsible for a potentially fatal bowel disease.As of this writing, ABT stock is trading around the $100 mark. The market capitalization of Abbott is $175 billion on estimated sales of $38.4 billion for 2024. A Formula for Legal TroubleThe case was filed on behalf of Margo Gill and her daughter, who developed necrotizing enterocolitis (NEC) and suffered severe brain damage after being given ...

High-yield dividend stocks are attractive investment options as they provide regular payouts regardless of market performance. Understanding dividend yield, which is a ratio showing annual dividend income per dollar invested, is crucial for comparing investments.The yield, expressed as a percentage of the current price, indicates the annual return on investment at the purchase price. Reinvesting dividends can significantly enhance returns due to compounding.Divide the annual dividend per share by the share ...

Alibaba (NYSE:BABA) stock is advancing more than 2%after Bloomberg reported that the Chinese e-commerce giant would start charging most merchants on its platforms a new fee. The conglomerate reportedly generates the majority of its e-commerce revenue with “customer management fees,” the news service noted.Meanwhile, Alibaba’s cloud unit increased the fees that it charges for domain names.Alibaba’s Price HikesThe e-commerce giant will begin requiring most merchants on its Chinese Taobao and Tmall e-commerce ...

Veteran investment commentator Mark Hulbert wrote an appropriately-timed commentary for MarketWatch on July 22 that discussed how Broadcom (NASDAQ:AVGO) stock and 24 others were most likely to crash.Hulbert highlighted the contrarian market indicator “U.S. Crash Confidence Index,” created in 1984 by Robert Shiller, the Yale professor best known for the CAPE ratio (cyclically adjusted price-to-earnings ratio), which is like the P/E ratio, except that the CAPE adjusts earnings to account for inflation.Accordi ...

Group 1: Market Overview - Former President Trump's improving odds for a second term are influencing investor behavior, with the "Trump trade" being priced into various sectors [1] - Current market volatility has increased due to President Biden's retreat and Vice President Harris' expected nomination, with Trump having a 57% chance of winning, slightly down from 58% [1] Group 2: Halliburton (HAL) - Halliburton is identified as a significant investment opportunity, particularly with a potential Trump victory that could enhance well production and energy demand [3] - The company has a strong financial profile, with a 17.7% operating margin and quarterly earnings growth of 16.2% year-on-year, alongside a free cash flow of $1.89 billion [3] - Analysts project an average price target of $44.55 per share, indicating HAL stock is currently trading about 23% below its fair value [3] Group 3: Steel Dynamics (STLD) - Steel Dynamics is another undervalued stock that could benefit from a potential Trump administration, particularly due to proposed tariffs on imports that would increase demand for domestic steel [5] - The company trades at approximately 7.5 times its estimated EBITDA, which is lower than recent industry transactions, and has a P/E ratio of 10.40 times compared to the industry average of 15.22 times [5] - Recent quarterly results showed revenues of $4.63 billion, exceeding forecasts by 4.3%, and an EPS of $2.72, beating estimates by 2% [5][6] Group 4: Marathon Digital (MARA) - Marathon Digital may benefit from Trump's favorable stance on Bitcoin, which could lead to regulatory changes impacting the company [7] - The recent Supreme Court ruling abolishing the Chevron deference may influence how the SEC classifies assets, potentially opening new avenues for MARA [7] - Despite a projected loss of $0.14 per share for the current quarter, the company's outlook remains strong with an expected EPS of $0.98 per share and a quarterly earnings growth of 184.1% year-on-year [8]

Microsoft (NASDAQ:MSFT) is a top stock to buy ahead of its fiscal 2024 Q4 earnings call after markets close on July 30. The company demonstrated solid growth across multiple business segments, specifically based on its expanding cloud services and AI  advancements. The company’s growth trajectory has a solid record of beating earnings per share estimates. Over the past three months, there have been 24 upward revisions for Microsoft stock. There were only six downward revisions for EPS estimates. Moreover, t ...

With the S&P 500 providing a paltry 1.32% dividend yield today, income-focused investors must be selective in their search for yield. That’s where the Dividend Aristocrats come in. These 66 S&P 500 companies have raised their dividends for at least 25 consecutive years.While Dividend Aristocrats may not be the most exciting stocks to own, there’s much to say about their staying power. Many of these companies have recession-resistant business models that generate consistent cash flows in almost any economic ...